Erectile Dysfunction

Vectura said in the second double-blind placebo-controlled trial of around 600 patients, VR004 improved erectile performance, with a rapid onset of action, and was well tolerated.

"Most interestingly, the company confirmed a rapid onset of action which was previously seen in its other study … We remain strong buyers of Vectura," Bridgewell Analyst Elizabeth Klein said.

Vectura plans to outlicense its sexual dysfunction program and Klein said, following these tests, she would expect it to be able to do so within the next year.

Shares in Vectura were up 1.4 percent at 88-1/2 pence in early trade, valuing the group at around 278 million pounds ($557.2 million).

ED, which affects more than 50 million men in the United States and European Union, is defined as the consistent inability to achieve and maintain an erection adequate for satisfactory sexual function.

© Reuters 2007.

All Rights Reserved.

Continued1.    Print This ArticlePrint This Article E-mail This ArticleEmail This Article RSS Headlines Newsletters Democrats Predict They Can Win Iraq Vote 10 Die As Storms Hit Texas-Mexico Border Russia Bids a Solemn Farewell to Yeltsin Most Sent Headlines Exclusive: O'Donnell Leaving 'The View'Born With the...

Read more...